CAT and Abbott: A David and Goliath Story

By Business Review Editor

Pharma Deals Review: Vol 2005 Issue 56 (Table of Contents)

Published: 1 Feb-2005

DOI: 10.3833/pdr.v2005.i56.722     ISSN: 1756-7874

Section: Features



Following a legal victory over Abbott Laboratories, Cambridge Antibody Technology (CAT) will now receive royalties on the rheumatoid arthritis therapeutic Humira#174; (adalimumab), at a rate more than double the one it was receiving before...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details